Formoterol delivered by Turbuhaler®: In pediatric asthma

Pediatric Drugs

Volumn 5, Issue 1, 2003, Pages 63-68

  Cheer, Susan M ^a   Warner, Gregory T ^a   Easthope, Stephanie E ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; FORMOTEROL OXIS; PLACEBO; SALMETEROL; TERBUTALINE;

ADOLESCENT; ASTHMA; BRONCHOSPASM; CHILD; CLINICAL TRIAL; DEVICE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037245140     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305010-00008     Document Type: Review

References (28)

1. Valacer DJ. Childhood asthma: causes, epidemiological factors and complications. Drugs 2000; 59 Suppl. 1: 1-8
2. Martinez FD. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol 1999 Oct; 104 (Suppl. Pt 2): S169-74
3. Warner JO, Naspitz CK, Cropp GJA. Third international pediatric consensus statement on the management of childhood asthma. Pediatr Pulmonol 1998 Jan; 25: 1-17
4. Anderson SD, Silverman M, Godfrey S, et al. Exercise-induced asthma: a review. Br J Dis Chest 1975; 69: 1-39
5. 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000; 29 (3): 221-34
6. Bartow RA, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998 Feb; 55 (2): 303-22
7. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42 (1): 115-37
8. AstraZeneca. Summary of product characteristics: Oxis Turbohaler 6 [online]. Available from URL: http://www.astrazeneca.co.uk/downloads/oxis6SPC(7982a) UK.pdf [Accessed 2002 Oct 8]
9. AstraZeneca. Oxis Turbohaler 12 [online]. Available from URL: http://www.astrazeneca.co.uk/downloads/SPC-Ocis-Turbohaler- 12-UK-7288.pdf [Accessed 2002 Dec 4]
10. Anderson GP, Lindén A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994 Mar; 7: 569-78
11. 2-andrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-60
12. Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated drypowder inhaler and spacer. Am J Respir Crit Care Med 2001 Jul 15; 164: 256-9
13. Hermansen MN, Nielsen KG, Buchvald FF, et al. Bronchodilation from formoterol and terbutaline has similar onset of action in asthmatic children [online]. Available from URL: https://www.ersnetsecure.org/public/prg_cogres.abstract?ww_i_presentation= 4925 [Accessed 2002 Sep 9]
14. Pohunek P, Matulka M, Rybnícek O, et al. Formoterol in Turbuhaler is faster and has a more beneficial ratio than salmeterol Diskhaler in asthmatic children [abstract no. P0610]. Eur Respir J 1998 Sep; 12 Suppl. 28: 87
15. 2-agonist, decreases airway responsiveness in children with asthma. Lung 1990; 168 Suppl.: 99-102
16. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992 Jun; 89: 1176-82
17. Boner AL, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994; 149: 935-9
18. Daubjerg P, Nielsen KG, Skov M, et al. Duration of action of formoterol and salbutamol dry-powder inhalation in the prevention of exercise-induced asthma in children. Acta Paediatr 1996; 85: 684-7
19. Nielsen KG, Skov M, Klug B, et al. Flow-dependent effect of formoterol dry-powder inhaled for the Aerolizer. Eur Respir J 1997; 10: 2105-9
20. Grönneröd TA, von Berg A, Schwabe G, et al. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000 Jul; 94 (7): 661-7
21. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650-6
22. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol (Oxis) Turbuhaler compared with placebo, in children (6-11 years) with asthma poorly controlled with inhaled corticosteroids [poster]. 2002 International Conference of the American Thoracic Society; 2002 May 17-22; Atlanta
23. Novartis. Foradil Aerolizer (formoterol furmate inhalation powder) [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/foradil.pdf [Accessed 2002 Mar 4]
24. von Berg A, Saxoni FP, Wille S, et al. 3-Month treatment with formoterol turbuhaler in children with asthma [abstract no. P0332]. Eur Respir J 1998 Sep; 12 Suppl. 28: 36
25. Everden PR, Manion V, Reynia S, et al. Formoterol Turbuhaler reduces the need for relief medication in children with mild to moderate asthma and improves quality of life [abstract no. P1939]. Eur Respir J 2001 Sep; 18 Suppl. 33: 291
26. Villa J, Kuna P, Egner J, et al. A 6-month comparison of the safety profiles of formoterol (Oxis) Turbuhaler as needed and terbutaline (Bricanyl) Turbuhaler as needed in asthmatic children on anti-inflammatory medication [poster]. 2002 International Conference of the American Thoracic Society; 2002 May 17-22; Altanta
27. Everden P, Lloyd A, Hutchinson J, et al. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respiratory Med 2002; 96: 250-8
28. 2-agonists (the RELIEF study) [online]. Available from URL: http://www.ersnetsecure.org/public/prg_congres.abstract?ww_i_presentation= 4971 [Accessed 2002 Oct 1]